Avinger, Inc. (NASDAQ:AVGR) Stock Closed Above Its 50 Day Moving Average

0
63

Shares of the company are trading at $0.34 a tad higher than the 50 day moving average of $0.31 and marginally over the 200 day moving average of $0.31. The 50 day moving average was up $0.03 whereas the 200 day moving average was up $0.03 or +9.2577%. (NASDAQ:AVGR) shares saw light trading volume with 91K shares changing hands in the last trading session. Trading volume was down 92.77% under the stocks average daily volume.

Short traders are more bearish lately as indicated by the change in short interest. The stock recorded a rise in short interest from September 15, 2017 to September 29, 2017 of 21.65%. Short shares grew from 2,171,200 to 2,641,164 over that timeframe. Days to cover decreased from 4.0 to 1.0 and the percentage of shorted shares is 0.11% as of September 29.

The following firms have recently changed their position in AVGR. Two Sigma Securities, LLC added to its ownership by buying 12,113 shares an increase of 116.8% in the quarter. Two Sigma Securities, LLC controls 22,481 shares worth $10,000. The total value of its holdings decreased 50.0%. As of the end of the quarter Ubs Group Ag had sold a total of 384 shares trimming its stake by 64.4%. The value of the total investment in Avinger, Inc. went from $1,000 to $0 a change of 100.0% for the reporting period.

As of quarter end Creative Planning had acquired 44,900 shares growing its position 404.5%. The value of the investment in Avinger, Inc. increased from $5,000 to $21,000 increasing 320.0% since the last quarter. As of quarter end Meeder Asset Management Inc had bought a total of 2,135 shares growing its holdings by 109.5%. The value in dollars increased from $1,000 to $2,000 a change of $1,000 quarter over quarter.

Avinger, Inc., launched on March 8, 2007, is a commercial-stage medical device company. The Company designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral arterial disease (PAD). The Company focuses on introducing products based on its lumivascular platform, which is an intravascular image-guided system. The Company manufactures and sells a suite of products in the United States and select European markets. The Business’s products include Lightbox imaging console, as well as its Wildcat, Kittycat and the Ocelot family of catheters, which are designed to allow physicians to penetrate a total blockage in an artery, known as a chronic total occlusion (CTO). The lumivascular platform offers real-time visualization of the inside of the artery during PAD treatment. The lumivascular platform consists of a capital component Lightbox and a range of disposable catheter products, including Ocelot, Ocelot PIXL, Ocelot MVRX and Pantheris..

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.